Juno Therapeutics, Inc.
JUNO
JUNO was delisted on the 5th of March, 2018.
237 hedge funds and large institutions have $3.7B invested in Juno Therapeutics, Inc. in 2017 Q4 according to their latest regulatory filings, with 55 funds opening new positions, 92 increasing their positions, 63 reducing their positions, and 26 closing their positions.
112% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 26
46% more repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 63
42% more call options, than puts
Call options by funds: $90.6M | Put options by funds: $63.9M
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
13% more funds holding
Funds holding: 210 → 237 (+27)
2% more capital invested
Capital invested by funds: $3.62B → $3.7B (+$89.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$59.2M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.3M |
| 3 |
Goldman Sachs
New York
|
+$33.6M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$28.7M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Crestline Management
Fort Worth,
Texas
|
-$85.7M |
| 2 |
State Street
Boston,
Massachusetts
|
-$35M |
| 3 |
D.E. Shaw & Co
New York
|
-$33.3M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$31.7M |
| 5 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$16M |
JUNO Hedge Fund Activity: Q4 2017 in Review
237 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Juno Therapeutics, Inc. (JUNO) for Q4 2017, worth a combined $3.7B — up 2.5% from $3.62B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new JUNO positions and 26 closed out — a net gain of 29 holders — while 92 added to existing stakes and 63 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $59.2M. The largest seller was Crestline Management, cutting an estimated $85.7M.
- 237 institutional investors held Juno Therapeutics, Inc. (JUNO) as of Q4 2017, up from 210 in Q3 2017.
- Funds reported $3.7B of Juno Therapeutics, Inc. stock for Q4 2017, up 2.5% quarter-over-quarter.
- 55 funds opened new Juno Therapeutics, Inc. positions in Q4 2017 and 26 closed out, a net change of +29 holders.
- The largest Juno Therapeutics, Inc. buyer in Q4 2017 was Janus Henderson Group, an estimated $59.2M added.
- The largest Juno Therapeutics, Inc. seller in Q4 2017 was Crestline Management, an estimated $85.7M sold.
Based on aggregated 13F filings for Q4 2017.